David B. Wright
King's College London
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David B. Wright.
Pulmonary Pharmacology & Therapeutics | 2013
David B. Wright; Thomas Trian; Sana Siddiqui; Chris D. Pascoe; Jill R. Johnson; Bart G. J. Dekkers; Shyamala Dakshinamurti; Rushita A. Bagchi; Janette K. Burgess; Varsha Kanabar; Oluwaseun O. Ojo
The biological responses of airway smooth muscle (ASM) are diverse, in part due to ASM phenotype plasticity. ASM phenotype plasticity refers to the ability of ASM cells to change the degree of a variety of functions, including contractility, proliferation, migration and secretion of inflammatory mediators. This plasticity occurs due to intrinsic or acquired abnormalities in ASM cells, and these abnormalities or predisposition of the ASM cell may alter the ASM response and in some cases recapitulate disease hallmarks of asthma. These phenotypic changes are ultimately determined by multiple stimuli and occur due to alterations in the intricate balance or reversible state that maintains ASM cells in either a contractile or synthetic state, through processes termed maturation or modulation, respectively. To elucidate the role of ASM phenotype in disease states, numerous in vitro studies have suggested a phenotypic switch in ASM primary cell cultures as an explanation for the plethora of responses mediated by ASM cells. Moreover, there is overwhelming evidence suggesting that the immunomodulatory response of ASM is due to the acquisition of a synthetic phenotype; however, whether this degree of plasticity is present in vivo as opposed to cell culture-based models remains speculative. Nonetheless, this review will give an overall scope of ASM phenotypic markers, triggers of ASM phenotype modulation and novel therapeutic approaches to control ASM phenotype plasticity.
Pulmonary Pharmacology & Therapeutics | 2013
David B. Wright; Pawan Sharma; Min Hyung Ryu; Paul-André Risse; Melanie Ngo; Harm Maarsingh; Cynthia Koziol-White; Aruni Jha; Andrew J. Halayko; Adrian R. West
Asthma is a chronic obstructive airway disease characterised by airway hyperresponsiveness (AHR) and airway wall remodelling. The effector of airway narrowing is the contraction of airway smooth muscle (ASM), yet the question of whether an inherent or acquired dysfunction in ASM contractile function plays a significant role in the disease pathophysiology remains contentious. The difficulty in determining the role of ASM lies in limitations with the models used to assess contraction. In vivo models provide a fully integrated physiological response but ASM contraction cannot be directly measured. Ex vivo and in vitro models can provide more direct assessment of ASM contraction but the loss of factors that may modulate ASM responsiveness and AHR, including interaction between multiple cell types and disruption of the mechanical environment, precludes a complete understanding of the disease process. In this review we detail key advantages of common in vivo, ex vivo and in vitro models of ASM contraction, as well as emerging tissue engineered models of ASM and whole airways. We also highlight important findings from each model with respect to the pathophysiology of asthma.
The Journal of Physiology | 2018
Yasin Shaifta; Charles E. MacKay; Nneka Irechukwu; Katie A. O'Brien; David B. Wright; Jeremy P. T. Ward; Greg A. Knock
Transforming growth‐factor‐β (TGF‐β) and RhoA/Rho‐kinase are independently implicated in the airway hyper‐responsiveness associated with asthma, but how these proteins interact is not fully understood. We examined the effects of pre‐treatment with TGF‐β on expression and activity of RhoA, Rho‐kinase and ARHGEF1, an activator of RhoA, as well as on bradykinin‐induced contraction, in airway smooth muscle. TGF‐β enhanced bradykinin‐induced RhoA translocation, Rho‐kinase‐dependent phosphorylation and contraction, but partially suppressed bradykinin‐induced RhoA activity (RhoA‐GTP content). TGF‐β enhanced the expression of ARHGEF1, while a small interfering RNA against ARHGEF1 and a RhoGEF inhibitor prevented the effects of TGF‐β on RhoA and Rho‐kinase activity and contraction, respectively. ARHGEF1 expression was also enhanced in airway smooth muscle from asthmatic patients and ovalbumin‐sensitized mice. ARHGEF1 is a key TGF‐β target gene, an important regulator of Rho‐kinase activity and therefore a potential therapeutic target for the treatment of asthmatic airway hyper‐responsiveness.
Pulmonary Pharmacology & Therapeutics | 2014
T. Koopmans; V. Anaparti; I. Castro-Piedras; P. Yarova; Nneka Irechukwu; Carl P. Nelson; Jose F. Perez-Zoghbi; X. Tan; Jeremy P. T. Ward; David B. Wright
Pulmonary Pharmacology & Therapeutics | 2013
David B. Wright; S. Tripathi; A. Sikarwar; K.T. Santosh; Jose F. Perez-Zoghbi; O.O. Ojo; Nneka Irechukwu; Jeremy P. T. Ward; Dedmer Schaafsma
Pulmonary Pharmacology & Therapeutics | 2013
David B. Wright; Thomas Trian; Sana Siddiqui; Chris D. Pascoe; Oluwaseun O. Ojo; Jill R. Johnson; Bart G. J. Dekkers; Shyamala Dakshinamurti; Rushita A. Bagchi; Janette K. Burgess; Varsha Kanabar
The Journal of Physiology | 2018
Yasin Shaifta; Charles E. MacKay; Nneka Irechukwu; Katie A. O'Brien; David B. Wright; Jeremy P. T. Ward; Greg A. Knock
European Respiratory Journal | 2013
David B. Wright; Yasin Shaifta; Vladimir A. Snetkov; Jeremy P. T. Ward
/data/revues/10945539/v26i1/S109455391200123X/ | 2013
David B. Wright; Pawan Sharma; Min Hyung Ryu; Paul-André Risse; Melanie Ngo; Harm Maarsingh; Cynthia Koziol-White; Aruni Jha; Andrew J. Halayko; Adrian R. West
american thoracic society international conference | 2012
Oluwaseun O. Ojo; David B. Wright; Tak H. Lee; Jeremy P. T. Ward